within Pharmacolibrary.Drugs.ATC.N;

model N06AA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 1.24 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.0115,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0205,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Desipramine is a tricyclic antidepressant (TCA) primarily used to treat major depressive disorder. It acts mainly as a norepinephrine reuptake inhibitor. While it has been largely replaced by newer antidepressants, desipramine is still approved and in use for depression and sometimes off-label for neuropathic pain and attention-deficit hyperactivity disorder (ADHD).</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in healthy adult volunteers (mixed sex), oral administration.</p><h4>References</h4><ol><li><p>Nichols, AI, et al., &amp; Paul, J (2013). Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults. <i>International clinical psychopharmacology</i> 28(2) 99–105. DOI:<a href=&quot;https://doi.org/10.1097/YIC.0b013e32835c1f49&quot;>10.1097/YIC.0b013e32835c1f49</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23221858/&quot;>https://pubmed.ncbi.nlm.nih.gov/23221858</a></p></li><li><p>Daniel, W, &amp; Melzacka, M (1992). A comparative study on desipramine pharmacokinetics in the rat brain after administration of desipramine or imipramine. <i>The Journal of pharmacy and pharmacology</i> 44(5) 429–432. DOI:<a href=&quot;https://doi.org/10.1111/j.2042-7158.1992.tb03638.x&quot;>10.1111/j.2042-7158.1992.tb03638.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1359059/&quot;>https://pubmed.ncbi.nlm.nih.gov/1359059</a></p></li><li><p>Harris, RZ, et al., &amp; Padhi, D (2007). Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. <i>European journal of clinical pharmacology</i> 63(2) 159–163. DOI:<a href=&quot;https://doi.org/10.1007/s00228-006-0129-8&quot;>10.1007/s00228-006-0129-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16680561/&quot;>https://pubmed.ncbi.nlm.nih.gov/16680561</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06AA01;
